Loading strategy tools...
Loading strategy tools...
Three vendors. One CMS reimbursement code. Wildly different workflows. This is the side-by-side a CMO, CIO, or vision champion needs before signing a contract.
Primary data from FDA, CMS, and peer-reviewed publications · Updated 2026-04-30
3
AUTONOMOUS VENDORS
$43.67
CMS 2025 REIMB
$29.14
HUMAN MD INTERP
1-in-4
CAHABA DETECTION RATE
CMS pays autonomous AI ($43.67 / CPT 92229) MORE than human MD interpretation ($29.14 / CPT 92228). This is the first time in medical history CMS has price-premiumed AI over human work. FQHCs are the natural buyer — high-volume diabetic panels, ophthalmology shortage, meaningful clinical gap. If your FQHC hasn't deployed DR AI yet, it's not because the economics don't work. It's because nobody has done the three-way comparison.
Primary source: CMS Physician Fee Schedule (CY 2025)
Decision Framework
Picking between LumineticsCore, EyeArt, and AEYE-DS isn't a tech spec bake-off. It's a question of what your FQHC actually does — Static screening? Multi-camera? Mobile?
Scenario 1
"We want the longest FDA track record + documented FQHC outcome data"
First FDA-authorized autonomous AI in any field of medicine (April 2018). Cahaba Medical Care (FQHC) detected previously-missed DR in 1-in-4 patients — the only public FQHC outcome data available.
Recommendation
LumineticsCore
Digital Diagnostics
Scenario 2
"We screen for both more-than-mild AND vision-threatening DR"
First FDA-cleared for both DR severity tiers. 96% sensitivity for more-than-mild DR; 92% for vision-threatening. Active California FQHC RCT at San Ysidro Health (DRES-POCAI, NCT06721351, 848 patients).
Recommendation
EyeArt
Eyenuk
Scenario 3
"We need portable / mobile / outreach screening (mobile vans, school-based, home visits)"
Only FDA-cleared autonomous AI for portable handheld screening (May 2024). Single-image-per-eye = fastest workflow. Rare/no dilation needed. Zero startup cost subscription model.
Recommendation
AEYE-DS
AEYE Health
Scorecard
Data sourced from FDA submissions, CMS Physician Fee Schedule, and vendor communications. Hover the decision frames above to highlight the winner.
Digital Diagnostics
FDA De Novo authorized April 2018 — first FDA-authorized autonomous AI in any field of medicine.
Sensitivity
87.2%
Specificity
90.7%
CPT
92229
Reimb
$43.67
Documented FQHC Customers
Eyenuk
510(k) cleared August 2020. Cleared with multiple cameras: Topcon NW400 (2023), Canon CR-2 AF, Canon CR-2 Plus AF.
Sensitivity
96% (more-than-mild DR), 92% (vision-threatening DR)
Specificity
88% (more-than-mild DR), 94% (vision-threatening DR)
CPT
92229
Reimb
$43.67
Documented FQHC Customers
AEYE Health
510(k) cleared November 2022; expanded May 2024 for portable handheld (first FDA-cleared autonomous AI for portable DR screening).
Sensitivity
93%
Specificity
91.4%
CPT
92229
Reimb
$43.67
Documented FQHC Customers
No publicly documented FQHC deployments
| Criterion | LumineticsCore | EyeArt | AEYE-DS |
|---|---|---|---|
FDA Authorization Date | April 2018Leader | August 2020 | November 2022 |
Sensitivity (DR detection) | 87.2% | 96% (more-than-mild DR), 92% (vision-threatening DR) | 93% |
Specificity (false-positive control) | 90.7% | 88% (more-than-mild DR), 94% (vision-threatening DR) | 91.4% |
CPT Code | 92229 | 92229 | 92229 |
2025 CMS Reimbursement | $43.67 | $43.67 | $43.67 |
EHR Integrations | Epic, OCHIN Epic, athenahealth, NextGen, eClinicalWorks | Epic, OCHIN Epic, athenahealth, NextGen, eClinicalWorks | Generic HL7/DICOM |
Documented FQHC Deployments | Cahaba Medical Care (FQHC); Tarzana Treatment Centers | San Ysidro Health (DRES-POCAI RCT); Henrietta Johnson Medical Center | None publicly documented |
Strengths
Limitations
Strengths
Limitations
Strengths
Limitations
Interactive Decision Wizard
If you're still not sure, let the wizard walk you through it. Four operational questions, one personalized recommendation based on your constraints.
Walk through 4 questions to get a recommendation: LumineticsCore (Digital Diagnostics), EyeArt (Eyenuk), or AEYE-DS (AEYE Health).
Step 1/4 · Deployment model
Real-World Outcomes
Cahaba Medical Care, an Alabama FQHC, deployed LumineticsCore (then IDx-DR) for autonomous DR screening among diabetic patients. In their patient population:
1-in-4
Patients with previously-undetected DR identified
$43.67
CPT 92229 reimbursement per scan
2018
Year FDA authorized the first autonomous medical AI — for eyes
Source: Digital Diagnostics — Cahaba Medical Care White Paper
Active CA RCT
An 848-patient randomized controlled trial at San Ysidro Health (San Diego) — the first CA FQHC to run a registered point-of-care AI RCT. EyeArt by Eyenuk integrated with OCHIN Epic. Funded by Moore Foundation + Kaiser AIM-HI. Results expected late 2026.
Study protocol — JAMA Network OpenBuyer's Checklist
No vendor publishes pricing. Every contract is negotiated. Use this list when you're on a call with a sales rep.
AI selection is one step of the launch. Here's the operational context.
Operational calendar with vendor selection in Week 2.
Open playbookROI calculator, 19 CA FQHC inventory, charity partners, workforce gaps.
Open strategyThe case for why — historical context of the first medical AI.
Read essay